These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35267651)

  • 1. Dual Effect of Combined Metformin and 2-Deoxy-D-Glucose Treatment on Mitochondrial Biogenesis and PD-L1 Expression in Triple-Negative Breast Cancer Cells.
    Repas J; Zupin M; Vodlan M; Veranič P; Gole B; Potočnik U; Pavlin M
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers
    Repas J; Peternel L; Sourij H; Pavlin M
    Front Endocrinol (Lausanne); 2023; 14():1216193. PubMed ID: 38116319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
    Wokoun U; Hellriegel M; Emons G; Gründker C
    Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profiling of attached and detached metformin and 2-deoxy-D-glucose treated breast cancer cells reveals adaptive changes in metabolome of detached cells.
    Repas J; Zügner E; Gole B; Bizjak M; Potočnik U; Magnes C; Pavlin M
    Sci Rep; 2021 Nov; 11(1):21354. PubMed ID: 34725457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.
    Tan X; Li Y; Hou Z; Zhang M; Li L; Wei J
    Exp Cell Res; 2023 Aug; 429(1):113647. PubMed ID: 37225011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy.
    Samuel SM; Varghese E; Satheesh NJ; Triggle CR; Büsselberg D
    Biomed Pharmacother; 2023 Aug; 164():114911. PubMed ID: 37224753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
    Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
    Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
    Gründker C; Wokoun U; Hellriegel M; Emons G
    J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
    Shao B; Li CW; Lim SO; Sun L; Lai YJ; Hou J; Liu C; Chang CW; Qiu Y; Hsu JM; Chan LC; Zha Z; Li H; Hung MC
    Am J Cancer Res; 2018; 8(9):1837-1846. PubMed ID: 30323975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
    Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
    Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.
    Cheong JH; Park ES; Liang J; Dennison JB; Tsavachidou D; Nguyen-Charles C; Wa Cheng K; Hall H; Zhang D; Lu Y; Ravoori M; Kundra V; Ajani J; Lee JS; Ki Hong W; Mills GB
    Mol Cancer Ther; 2011 Dec; 10(12):2350-62. PubMed ID: 21992792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Deoxy-d-glucose increases GFAT1 phosphorylation resulting in endoplasmic reticulum-related apoptosis via disruption of protein N-glycosylation in pancreatic cancer cells.
    Ishino K; Kudo M; Peng WX; Kure S; Kawahara K; Teduka K; Kawamoto Y; Kitamura T; Fujii T; Yamamoto T; Wada R; Naito Z
    Biochem Biophys Res Commun; 2018 Jun; 501(3):668-673. PubMed ID: 29753740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Metformin on JNK Signaling Pathway and PD-L1 Expression in Triple Negative Breast Cancer.
    Wang R; Zhao Y
    Cancer Manag Res; 2024; 16():259-268. PubMed ID: 38585433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumol enhances the anti-tumor effects of metformin via suppressing epithelial-mesenchymal transition in triple-negative breast cancer.
    Wang G; Dong Y; Liu H
    Ann Transl Med; 2020 Aug; 8(15):946. PubMed ID: 32953746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
    Cheung A; Chenoweth AM; Quist J; Sow HS; Malaktou C; Ferro R; Hoffmann RM; Osborn G; Sachouli E; French E; Marlow R; Lacy KE; Papa S; Grigoriadis A; Karagiannis SN
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Integrated Proteomic and Glycoproteomic Investigation Reveals Alterations in the
    Ma C; Tsai HY; Zhang Q; Senavirathna L; Li L; Chin LS; Chen R; Pan S
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.